Fact-checked by Grok 2 weeks ago

Antispasmodic

Antispasmodics, also referred to as spasmolytics, are a class of medications designed to suppress or relieve spasms and contractions in muscles, particularly those lining hollow organs such as the gastrointestinal, urinary, and biliary tracts. These agents achieve their effects through diverse pharmacological mechanisms, including inhibition of muscarinic receptors, blockade of calcium channels, and direct relaxation of cells, thereby reducing excessive contractility responsible for cramping and discomfort. The use of antispasmodics dates back to ancient times, with natural compounds from plants like (source of atropine) and opium poppy employed for their spasmolytic effects as early as 4000 BC. Indigenous South American cultures used extracts for muscle relaxation since at least 1504, while modern synthetic antispasmodics, such as dicyclomine, emerged in the mid-20th century, building on alkaloids isolated in the . The primary therapeutic applications of antispasmodics center on functional gastrointestinal disorders, where they alleviate symptoms like , , and altered bowel habits in conditions such as , with clinical trials demonstrating symptom improvement in up to 82% of patients treated with agents like dicyclomine compared to 55% on . Beyond the gut, they are employed for urinary tract issues, including and incontinence, as seen with drugs like that directly antagonize spasms while inhibiting muscarinic actions. They also find use in and procedural settings like to facilitate relaxation. Antispasmodics are categorized into several subclasses based on their mechanisms: /antimuscarinic agents (e.g., dicyclomine, , and hyoscine), which block excitatory and reduce motility by limiting calcium transport; calcium channel inhibitors (e.g., , ), which prevent calcium influx to inhibit contractions; and direct smooth muscle relaxants (e.g., , citrate), which modulate channels like sodium and calcium to decrease muscle . Many exhibit excellent safety profiles with low incidence of adverse effects, though anticholinergics may cause dry mouth, , or in susceptible individuals. Natural compounds from , such as essential oils with spasmolytic properties, represent an emerging area of research for complementary antispasmodic therapy.

Introduction

Definition

Antispasmodics are pharmaceutical agents or natural substances that suppress muscle spasms by reducing excessive contractility, primarily targeting muscles in visceral organs or skeletal muscles. These compounds alleviate involuntary contractions without broadly impairing muscle function, distinguishing them from more generalized relaxants. The term "antispasmodic" originates from the Greek-derived prefix "anti-" (against) combined with "spasmodic," which refers to sudden, involuntary muscle contractions or ; a common synonym is "spasmolytic." This nomenclature reflects their role in counteracting spasmodic activity, a concept recognized since the late . In contrast to general muscle relaxants, which often produce and overall that can lead to , antispasmodics specifically inhibit spasm formation, particularly in tissues, while preserving normal and voluntary movement. Antispasmodics are widely employed in for managing disorders involving involuntary contractions, with significant use in gastrointestinal conditions affecting approximately 4-5% of the population in and . Early applications drew from natural remedies, such as plant extracts exhibiting spasmolytic effects.

Historical Background

This early ethnopharmacological practice laid foundational insights into muscle-relaxing agents, influencing later pharmacological explorations of plant-based spasmolytics. In the 19th and early 20th centuries, the development of synthetic anticholinergics marked a significant advancement, with alkaloids such as atropine—first isolated in 1832—being adapted for treating gastrointestinal spasms. These compounds, derived from natural sources like , were refined into more targeted formulations to reduce contractions in conditions involving abdominal cramping, transitioning from crude extracts to pharmaceutically standardized agents. Mid-20th-century milestones included the introduction of in 1955, an early synthetic antispasmodic noted for its muscle-relaxant effects alongside properties, which broadened therapeutic applications for tension-related spasms. Concurrently, dicyclomine emerged in the 1950s as a key agent for (IBS), approved by the FDA in 1950 to specifically address intestinal spasms. From the late 20th to the , the field shifted toward more targeted therapies, exemplified by like , registered in 1975 for gastrointestinal disorders. This era also saw expanded evidence from clinical trials in the 1980s onward supporting antispasmodics in IBS management, refining their role through rigorous testing. Over time, classification evolved from broad spasmolytics encompassing various muscle relaxants to distinct categories for (e.g., gastrointestinal agents) and (e.g., treatments) in modern , enabling precise therapeutic differentiation.

Types of Antispasmodics

Smooth Muscle Antispasmodics

Smooth muscle antispasmodics are primarily classified into three categories based on their mechanisms: anticholinergics (also known as antimuscarinics), inhibitors, and direct relaxants. Anticholinergics include agents such as dicyclomine, , and . Many of these are derived from or mimic natural tropane alkaloids from like . Calcium inhibitors include and . Direct relaxants encompass drugs like and , which exert their effects independently of pathways. These agents target visceral smooth muscles, particularly in the , biliary system, and urinary tract, where they help alleviate spasms in internal organs. Unlike skeletal muscle antispasmodics, which address voluntary muscle issues, these focus exclusively on involuntary visceral . Availability varies by region and formulation. is often accessible over-the-counter in forms like tablets, particularly in and , while prescription status applies elsewhere. is primarily available in as a prescription for conditions involving spasms.

Skeletal Muscle Antispasmodics

Skeletal muscle antispasmodics, also known as skeletal muscle relaxants, are primarily classified into two categories: centrally acting agents and direct-acting agents. Centrally acting agents, such as , , , and , exert their effects through the to reduce muscle spasms. Direct-acting agents, exemplified by , target skeletal muscle fibers more peripherally without primary reliance on central mechanisms. These medications differ from smooth muscle antispasmodics, which address involuntary visceral muscle contractions rather than voluntary activity. These agents are mainly indicated for managing arising from neurological conditions, including , , and . Centrally acting types often produce effects due to their penetration and modulation within the , which can influence activity and contribute to overall muscle relaxation. This CNS involvement distinguishes them from peripheral approaches and underscores their role in alleviating heightened in neurological contexts. Skeletal muscle antispasmodics are generally available only by prescription to ensure appropriate monitoring. For acute musculoskeletal conditions, guidelines recommend short-term use, typically 2 to 4 weeks, to minimize risks and tolerance development. For chronic , longer-term use may be appropriate under medical supervision.

Mechanisms of Action

For Smooth Muscle

Smooth muscle antispasmodics primarily exert their effects through antagonism of muscarinic receptors, particularly the , , and M3 subtypes, which inhibits parasympathetic stimulation and thereby reduces contraction in visceral organs. For instance, dicyclomine acts as a competitive at M3 receptors in the , blocking binding and preventing the downstream activation of , production, and calcium release that drives contraction. This selective blockade diminishes excitatory signaling without broadly disrupting other autonomic functions. Additional mechanisms involve direct relaxation of smooth muscle via inhibition of phosphodiesterase enzymes or blockade of calcium channels. Phosphodiesterase inhibitors, such as drotaverine, elevate intracellular cyclic adenosine monophosphate (cAMP) levels by preventing its degradation, which activates protein kinase A and promotes myosin light chain phosphatase activity, leading to dephosphorylation and relaxation of contractile elements. Calcium channel blockers like pinaverium target L-type voltage-gated channels, inhibiting extracellular calcium influx necessary for depolarization and cross-bridge formation in smooth muscle cells, thereby preventing sustained contraction. Otilonium bromide further modulates this by antagonizing neurokinin-2 (NK2) receptors, reducing tachykinin-mediated excitatory neurotransmission that amplifies smooth muscle tone. These actions result in decreased and reduced basal tone in gastrointestinal and , with minimal impact on due to the drugs' poor penetration into systemic circulation and tissue selectivity. studies using isolated strip preparations from human or animal colon have demonstrated this efficacy; for example, pinaverium and otilonium significantly attenuate contractility induced by agonists like carbachol or , shifting dose-response curves rightward and confirming receptor-mediated inhibition without at therapeutic concentrations.

For Skeletal Muscle

Skeletal muscle antispasmodics primarily target central and peripheral pathways to alleviate , a condition characterized by increased and exaggerated reflexes due to disrupted neural control. Central mechanisms involve enhancing inhibitory within the , where agents like act as agonists at GABA-B receptors on pre- and postsynaptic neurons, leading to hyperpolarization of motor neurons and diminished excitatory release, thereby reducing spastic activity. Another key central pathway is alpha-2 adrenergic agonism, exemplified by , which activates presynaptic alpha-2 receptors in the and to increase inhibition of motor neurons through noradrenergic modulation, suppressing the release of excitatory transmitters and potentiating presynaptic inhibition. Additional mechanisms include 's central action, which inhibits norepinephrine and serotonin in the , dampening polysynaptic arcs and reducing tonic somatic motor activity by affecting alpha and gamma motor neurons. In contrast, operates peripherally by binding to ryanodine receptors in the of fibers, inhibiting calcium release and thereby interfering directly with excitation-contraction coupling without altering neural transmission. These actions collectively result in physiological effects such as decreased excitability and attenuation of monosynaptic es, as evidenced by reductions in amplitude in clinical studies with and , indicating diminished spinal gain in spastic conditions.

Medical Uses

Gastrointestinal Applications

Antispasmodics, particularly those targeting relaxation, play a key role in managing gastrointestinal disorders characterized by spasms and cramping, with (IBS) being the primary indication. In IBS, these agents are employed as a to alleviate and by reducing intestinal and visceral sensitivity. For instance, has demonstrated efficacy in improving IBS symptoms compared to in randomized controlled trials lasting 4 weeks to 3 months. Similarly, dicyclomine hydrochloride, an antispasmodic, has been shown to decrease and improve overall patient condition in early RCTs from the . The American Gastroenterological Association () conditionally recommends antispasmodics for IBS symptom relief based on low-quality evidence from network meta-analyses indicating superior response rates over for pain reduction. The 2025 Seoul Consensus on IBS guidelines also supports the use of antispasmodics for alleviating global symptoms and , noting common adverse effects such as dry mouth, , and . Beyond IBS, antispasmodics are used adjunctively in other gastrointestinal conditions involving spasms, such as and . In , agents like provide relief from spasms by inhibiting muscarinic receptors in visceral , often combined with analgesics for acute episodes. For , antispasmodics such as dicyclomine or help manage cramping pain during uncomplicated cases, supporting symptom control alongside antibiotics if is present. These medications are also administered to mitigate spasms during gastrointestinal procedures like or in the postoperative period following , where intravenous forms facilitate rapid onset. Efficacy evidence for antispasmodics in gastrointestinal applications stems from systematic reviews and guidelines emphasizing their role in targeted pain relief rather than comprehensive symptom resolution. The 2008 review found antispasmodics more effective than for IBS, with a of 0.68 for symptom persistence (32% reduction). While the of (ACG) 2021 guidelines advise against routine use for overall IBS symptoms due to inconsistent evidence, they acknowledge potential benefits for isolated cramping when integrated with lifestyle modifications. Administration of antispasmodics for gastrointestinal spasms typically involves oral formulations for chronic management, such as dicyclomine 10-20 mg up to four times daily, while intravenous options like are reserved for acute settings to achieve faster relaxation. These treatments are often combined with dietary advice, including increased soluble intake, to enhance overall efficacy in conditions like IBS without exacerbating spasms.

Other Applications

Antispasmodics play a significant role in managing urological conditions by relaxing the of the , thereby alleviating symptoms associated with (OAB) and urinary spasms. , an agent, is commonly prescribed for OAB, where it reduces urinary urgency, frequency, and incontinence by inhibiting muscarinic receptors in the smooth muscle. Clinical studies have demonstrated its in improving control, with extended-release formulations providing sustained symptom relief over 24 hours. Additionally, antispasmodics like are used post-operatively to mitigate spasms following procedures such as or surgery, helping to prevent discomfort and promote recovery. In respiratory medicine, antispasmodics, particularly anticholinergics, serve as adjunctive therapy for in conditions like (COPD) and . Ipratropium bromide, administered via , acts as a by blocking muscarinic receptors in the airways, thereby reducing and improving airflow. It is especially useful in COPD for long-term control of reversible , often combined with beta-agonists for enhanced efficacy in acute exacerbations. Guidelines recommend ipratropium for patients with persistent symptoms despite short-acting bronchodilators, as it provides additive benefits without significant cardiac side effects. For neurological and musculoskeletal disorders, antispasmodics target arising from lesions. In (MS) and (SCI), intrathecal delivery via an implanted pump effectively reduces severe by acting on GABA-B receptors in the , allowing for lower doses and fewer systemic effects compared to oral administration. Long-term studies show sustained improvements in , , and , with complication rates around 1% per month, primarily related to issues. For acute due to musculoskeletal strains, is employed short-term as an adjunct to rest and analgesics, where it centrally depresses motor activity to relieve spasms and associated pain. Meta-analyses indicate modest pain reduction and functional improvement in the first week of , benefiting approximately one in three to nine patients over . Beyond these primary areas, antispasmodics find utility in gynecological and procedural contexts. For , agents like provide relief by relaxing uterine , with randomized trials showing efficacy comparable to aspirin in reducing intensity. Similarly, combinations such as with have demonstrated superior effects over in primary . In endoscopic procedures, antispasmodics like facilitate visualization by minimizing gastrointestinal spasms, shortening insertion time and improving diagnostic yield without increasing adverse events. For spastic , has shown promise in clinical trials, reducing abnormal in cranial and limb forms, with doses up to 36 mg daily tolerated in open-label studies.

Side Effects and Contraindications

Adverse Effects

Antispasmodics, particularly those targeting such as dicyclomine, commonly produce adverse effects due to their mechanism of blocking muscarinic receptors. These include dry mouth (reported in 33% of patients in clinical trials), (27%), , , and . Such effects are dose-dependent and can lead to discontinuation in up to 9% of users. Skeletal muscle antispasmodics, exemplified by , frequently cause effects, including drowsiness (occurring in 29-38% of patients across doses in controlled studies), , and . These symptoms contribute to impaired alertness and coordination, affecting daily activities. Less common adverse effects across both types include allergic reactions such as skin rash or , which are rare but require immediate medical attention. Long-term use of skeletal muscle agents like carries a risk of and , with potential for due to properties. Additionally, rare cases of have been associated with , though significant liver injury is uncommon. Adverse effects are generally dose-dependent and more pronounced in elderly patients owing to age-related reductions in hepatic and renal metabolism, leading to higher drug accumulation and increased sensitivity to anticholinergic and sedative actions. Long-term use of anticholinergic antispasmodics has been linked to an increased risk of dementia and cognitive impairment in older adults. Monitoring is essential in this population to mitigate risks like falls and cognitive impairment.

Precautions and Interactions

Antispasmodics, whether targeting smooth or skeletal muscle, require careful consideration in patients with certain medical conditions due to their potential to exacerbate underlying issues or cause significant adverse effects. Contraindications and precautions vary by class, but common themes include avoidance in cases of hypersensitivity, severe hepatic or renal impairment, and conditions that could worsen with central nervous system (CNS) depression or anticholinergic activity. For instance, patients with glaucoma, myasthenia gravis, or obstructive gastrointestinal or urinary tract disorders should generally avoid smooth muscle antispasmodics, as these agents can increase intraocular pressure or impair muscle function. Similarly, skeletal muscle antispasmodics are contraindicated in individuals with a history of hypersensitivity or, for drugs like cyclobenzaprine, recent use of monoamine oxidase inhibitors (MAOIs) due to risks of hypertensive crisis or serotonin syndrome. In special populations, precautions are particularly stringent. Elderly patients are more susceptible to anticholinergic effects from smooth muscle antispasmodics, such as urinary retention, constipation, and confusion, necessitating dose adjustments or avoidance. For skeletal muscle agents like baclofen, geriatric use heightens risks of drowsiness, falls, and respiratory depression, especially when combined with other sedatives. Pregnancy and breastfeeding warrant caution across both classes; smooth muscle antispasmodics like dicyclomine are contraindicated in nursing mothers due to potential infant toxicity, while skeletal agents such as cyclobenzaprine are typically avoided unless benefits outweigh risks, given limited safety data. Abrupt discontinuation of baclofen, in particular, can precipitate withdrawal symptoms including hallucinations, seizures, or rhabdomyolysis, requiring gradual tapering under medical supervision. Drug interactions pose significant risks with antispasmodics, primarily through additive CNS depression or enhanced pharmacological effects. antispasmodics, often s, can potentiate effects of other drugs (e.g., antihistamines or antidepressants), leading to severe dry mouth, , or ; antacids may reduce absorption if taken concurrently. antispasmodics like interact dangerously with MAOIs, agents (e.g., SSRIs), or opioids, increasing the risk of , , or overdose. Baclofen's CNS depressant properties amplify sedation when combined with alcohol, benzodiazepines, or opioids, potentially causing profound drowsiness, coma, or death. In all cases, patients should inform healthcare providers of all concurrent medications, including over-the-counter products, to mitigate these interactions.

References

  1. [1]
    Antispasmodic Effect of Essential Oils and Their Constituents
    The antispasmodic (spasmolytic) effect of drugs is commonly used for the reduction of excessive smooth muscle contractility, responsible for cramping and ...Missing: general definition
  2. [2]
    [PDF] DITROPAN (oxybutynin chloride) Tablets and Syrup DESCRIPTION ...
    CLINICAL PHARMACOLOGY. Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on ...
  3. [3]
    Antispasmodics for Chronic Abdominal Pain - PubMed Central - NIH
    Anticholinergic/antimuscarinic agents inhibit GI smooth muscle contraction, in part, by blocking calcium transport through calcium channels (31); furthermore, ...
  4. [4]
    [PDF] Bentyl (dicyclomine hydrochloride) capsules label
    The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat achlorhydria and those used to ...<|control11|><|separator|>
  5. [5]
    Role of antispasmodics in the treatment of irritable bowel syndrome
    Antispasmodics are a group of drugs that have been used in the treatment of IBS for decades. Alverine citrate, a spasmolytic, decreases the sensitivity of ...
  6. [6]
    Antispasmodic drugs in colonoscopy: a review of their ...
    Antispasmodic drugs are cheap, effective and generally safe. They may improve outcomes in colonoscopy, however their use has not been consistent or widespread.
  7. [7]
    Antispasmodic Potential of Medicinal Plants - PubMed Central - NIH
    Nov 11, 2021 · Drugs with antispasmodic effects are normally applied for the symptomatic treatment of contraction and cramping of smooth muscles in ...
  8. [8]
    Antispasmodic Medication: Uses & Side Effects - Cleveland Clinic
    Antispasmodics are medications that help relax the smooth muscles that line the walls of your internal organs.Hyoscyamine tablets · Colon Spasm · Tolterodine Tablets · Atropine
  9. [9]
    Antispasmodic - an overview | ScienceDirect Topics
    Antispasmodic agents are defined as compounds that reduce the excessive contractility of smooth-muscle cells, commonly used to alleviate abdominal cramping, ...Missing: etymology | Show results with:etymology
  10. [10]
    antispasmodic, adj. & n. meanings, etymology and more
    The earliest known use of the word antispasmodic is in the late 1600s. OED's earliest evidence for antispasmodic is from 1681. antispasmodic is formed from ...
  11. [11]
    Muscle Relaxers: What They Are, Uses, Side Effects & Types
    Providers mainly prescribe antispasmodic skeletal muscle relaxants for musculoskeletal and myofascial pain, especially lower back pain, and muscle spasms.
  12. [12]
    Muscle relaxants for non‐specific low‐back pain - PMC
    Muscle relaxants can be divided into two main categories: antispasmodic and antispasticity medications. Antispasmodics are used to decrease muscle spasm ...
  13. [13]
    Natural Antispasmodics: Source, Stereochemical Configuration, and ...
    Antispasmodic compounds are currently used to reduce anxiety, emotional and musculoskeletal tension, and irritability. Although most of the available ...
  14. [14]
    DIGEST REPORT ANTICHOLINERGIC CHEMICALS - NCBI - NIH
    After the first isolation of atropine from plant material in 1832, the actions of this group of alkaloids were identified rapidly. By 1875, Ringer (2) was able ...
  15. [15]
    Meprobamate-tranquilizer or anxiolytic? A historical perspective
    Meprobamate was the first successful anti-anxiety drug of the modern era. On the 50th anniversary of its introduction, the authors trace the development of its ...
  16. [16]
    Dicyclomine Hydrochloride - Drug Targets, Indications, Patents
    Dicyclomine Hydrochloride, marketed as BENTYL, is an antispasmodic and anticholinergic medication that was approved for use in the USA in 1950 for the treatment ...Missing: 1950s | Show results with:1950s<|control11|><|separator|>
  17. [17]
    Pinaverium bromide - Wikipedia
    It belongs to a drug group called antispasmodics and acts as a calcium channel blocker in helping to restore the normal contraction process of the bowel.Missing: 1970s | Show results with:1970s
  18. [18]
    Antispasmodic - an overview | ScienceDirect Topics
    Antispasmodics are used in IBS mainly as treatment for abdominal pain and cramping. The rationale is that they attenuate increased baseline and post-prandial ...
  19. [19]
    Can Antispasmodics Treat IBS? - Verywell Health
    Types of Antispasmodics for IBS. There are two types of antispasmodic medications used for IBS: anticholinergics and direct smooth muscle relaxants.
  20. [20]
    Antispasmodics for Chronic Abdominal Pain: Analysis of...
    Data for the prevalence of CAPS are currently lacking. Alterations in GI motility and visceral sensation play a role in the development of abdominal pain in ...
  21. [21]
    Antispasmodics | Concise Medical Knowledge - Lecturio
    Jan 24, 2025 · Antispasmodic agents are a group of medications used to reduce excessive gastrointestinal smooth muscle contractility and spasm.
  22. [22]
    Phloroglucinol-Derived Medications are Effective in Reducing Pain ...
    Nov 29, 2022 · These compounds have been on the market for many years for the management of urinary and biliary tract pain related to muscle spasm.
  23. [23]
    Beauty of the beast: anticholinergic tropane alkaloids in therapeutics
    Sep 16, 2022 · Hence, they are of great clinical importance and are used as antiemetics, anesthetics, antispasmodics, bronchodilator and mydriatics. They also ...2 Tropane Alkaloids · 2.2 Anticholinergic Action · 2.4 Tropane Alkaloid...
  24. [24]
    dicyclomine | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
    Comment: Dicyclomine is a non-selective muscarinic acetylcholine receptor antagonist. Click here for help. Ligand Activity Visualisation Charts.<|separator|>
  25. [25]
    What is the mechanism of Mebeverine Hydrochloride?
    Jul 17, 2024 · By blocking calcium channels, Mebeverine reduces the influx of calcium, thereby relaxing the smooth muscles and preventing spasms.Missing: pharmacology papaverine-
  26. [26]
    Hyoscine butylbromide: a review of its use in the treatment ... - PubMed
    It was first registered in Germany in 1951 and marketed in 1952, and has since become available worldwide both as a prescription drug and as an over-the-counter ...
  27. [27]
    Buscopan® | to relieve abdominal pain & cramps
    Buscopan® is available behind the pharmacist's counter without a prescription. Ask ... Once you take Buscopan®, its active ingredient hyoscine butylbromide ...
  28. [28]
    Efficacy of otilonium bromide in irritable bowel syndrome: a pooled ...
    Jan 16, 2017 · OB is more effective than placebo in IBS treatment. Therapeutic benefits are significant after 10 weeks and are maximal after 15 weeks of treatment.
  29. [29]
    Diet or medication in primary care patients with IBS - Gut
    Oct 23, 2025 · Background In Europe, IBS is commonly treated with musculotropic spasmolytics (eg, otilonium bromide, OB). In tertiary care, a low fermentable ...
  30. [30]
    List of Skeletal Muscle Relaxants + Uses & Side Effects - Drugs.com
    Apr 17, 2023 · These are called centrally acting muscle relaxants and examples include baclofen, methocarbamol, and tizanidine. Others act directly on muscle ...
  31. [31]
    Skeletal muscle relaxants: Nursing pharmacology - Osmosis
    Centrally-acting muscle relaxants include cyclobenzaprine, methocarbamol, metaxalone, chlorzoxazone, tizanidine, baclofen, carisoprodol, and orphenadrine. Other ...
  32. [32]
    Muscle Relaxants, Centrally Acting Agents | DrugBank Online
    Cyclobenzaprine, A skeletal muscle relaxant that works on the brainstem to treat muscle spasms of local origin. Dantrolene, A direct-acting skeletal muscle ...
  33. [33]
    Tizanidine - an overview | ScienceDirect Topics
    Tizanidine is a centrally acting muscle relaxant that, through its alpha-2 adrenergic agonist properties, is thought to prevent the release of excitatory amino ...
  34. [34]
    Skeletal Muscle Relaxants | Palliative Care Network of Wisconsin
    Skeletal muscle relaxants (SMRs) are a heterogeneous class of medications used for the management of spasticity or muscle spasms.Missing: evolution classification smooth modern
  35. [35]
    Considerations for the Appropriate Use of Skeletal Muscle ...
    In general, muscle relaxants are controversial alternatives that have efficacy in nonspecific back pain but carry risks of adverse effects and increased cost.Class Overview · Antispasmodic Agents · Antispasmodic And...
  36. [36]
    Baclofen - StatPearls - NCBI Bookshelf - NIH
    Baclofen (β-[4-chlorophenyl]-γ-aminobutyric acid) is an agonist at the β subunit of gamma-aminobutyric acid on mono- and polysynaptic neurons at the spinal cord ...Baclofen · Administration · Adverse Effects
  37. [37]
    Cyclobenzaprine: Uses, Interactions, Mechanism of Action - DrugBank
    Cyclobenzaprine is a skeletal muscle relaxant that works on areas of the brainstem to reduce skeletal muscle spasm, though its exact pharmacodynamic ...Pharmacology · Products · Spectra
  38. [38]
    Tizanidine - StatPearls - NCBI Bookshelf
    Tizanidine is an FDA-approved drug for managing spasticity. It is a centrally acting alpha-2 receptor agonist. Tizanidine effectively works with spasticity
  39. [39]
    Choosing a Skeletal Muscle Relaxant - AAFP
    Aug 1, 2008 · Skeletal muscle relaxants are indicated for short-term use; therefore, multiple modalities (e.g., physical therapy, adjunctive analgesics) may ...
  40. [40]
    Dicyclomine | C19H35NO2 | CID 3042 - PubChem - NIH
    Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the ...
  41. [41]
    dicyclomine hydrochloride tablet - DailyMed - NIH
    Animal studies indicate that this action is achieved via a dual mechanism: a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor ...
  42. [42]
    Drotaverine | C24H31NO4 | CID 1712095 - PubChem - NIH
    Inhibition of PDE4 leads to elevated levels of cAMP, leading to smooth muscle relaxation. Recent research showed that low levels of cAMP have been associated ...
  43. [43]
    Effect of pinaverium bromide on stress-induced colonic smooth ... - NIH
    Pinaverium inhibits the calcium influx through L-type channels; decreases the contractile response to many kinds of agonists and regulates the stress-induced ...
  44. [44]
    Pharmacotherapy for Irritable Bowel Syndrome - PMC
    Otilonium bromide targets not only L- and T-type calcium channels, but also muscarinic type 2 and tachykinin NK2 receptors, possibly contributing to its ...
  45. [45]
    Effect of Pinaverium Bromide on Stress-Induced Colonic Smooth ...
    Pinaverium inhibits the calcium influx through L-type channels; decreases the contractile response to many kinds of agonists and regulates the stress-induced ...
  46. [46]
    Baclofen therapeutics, toxicity, and withdrawal: A narrative review
    Mechanism of action. Baclofen is an agonist for gamma-aminobutyric acid (GABA)B receptors on pre- and postsynaptic neurons in the central nervous system (CNS) ...
  47. [47]
    A Review of Spasticity Treatments - PubMed Central - NIH
    It works pre- and postsynaptically as a gamma aminobutylic acid (GABA) B agonist at the spinal level14 and binds to its receptors, leading to membrane ...
  48. [48]
    Tizanidine | C9H8ClN5S | CID 5487 - PubChem
    Tizanidine reduces spasticity by increasing presynaptic inhibition of motor neurons through agonist action at a2-adrenergic receptor sites. Toxin and Toxin ...
  49. [49]
    Potent suppression of stretch reflex activity after systemic or spinal ...
    The mechanism of tizanidine-mediated anti-spasticity effect has been demonstrated to be the result of potentiation of presynaptic inhibition, suppression of ...
  50. [50]
    Cyclobenzaprine | C20H21N | CID 2895 - PubChem - NIH
    A proposed mechanism for cyclobenzaprine includes inhibition of norepinephrine and serotonin reuptake, factors known to inhibit prostaglandin and nitric oxide.
  51. [51]
    Cyclobenzaprine - StatPearls - NCBI Bookshelf - NIH
    Cyclobenzaprine is a tricyclic amine salt that works in the central nervous system (CNS) as a depressant that reduces muscle hyperactivity.Missing: norepinephrine reuptake
  52. [52]
    Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by ...
    Oct 24, 1997 · The skeletal muscle relaxant dantrolene inhibits the release of Ca2+ from the sarcoplasmic reticulum during excitation-contraction coupling.
  53. [53]
    Essential Role of Calmodulin in RyR Inhibition by Dantrolene - PMC
    Dantrolene is a well known inhibitor of Ca2+ release in skeletal muscle (Hainaut and Desmedt, 1974) that has been used clinically as the treatment of malignant ...
  54. [54]
    Intrathecal baclofen and the H-reflex - PubMed
    In each patient, spasticity was reduced following intrathecal baclofen and in four patients there was a reduction in the amplitude of the H reflex and Hmax/Mmax ...
  55. [55]
    Effect of intrathecal baclofen on the monosynaptic reflex in humans
    Intrathecal baclofen is a very powerful antispastic agent. Its mechanism of action on the monosynaptic H-reflex in spinal patients was investigated.
  56. [56]
    Treatment of the irritable bowel syndrome with Bentyl (dicyclomine ...
    Dicyclomine hydrochloride 40 mg 4 times a day is superior to placebo in improving the overall condition of the patient, decreasing abdominal pain, decreasing ...Missing: RCTs 1980s
  57. [57]
    AGA Clinical Practice Guideline on the Pharmacological ...
    In patients with IBS, the AGA suggests against using SSRIs, Conditional, Low. 7. In patients with IBS, the AGA suggests using antispasmodics, Conditional, Low ...
  58. [58]
    Effect of fibre, antispasmodics, and peppermint oil in the treatment of ...
    Nov 14, 2008 · Fibre, antispasmodics, and peppermint oil were all more effective than placebo in the treatment of irritable bowel syndrome.Results · Antispasmodics · Discussion
  59. [59]
    Diverticulitis medication: Types and other treatments
    May 17, 2024 · Doctors may recommendTrusted Source acetaminophen (Tylenol) or antispasmodic such as dicyclomine (Bentyl) and hyoscyamine (NuLev) for pain ...Missing: biliary colic
  60. [60]
    Use of antispasmodics for the treatment of abdominal pain
    Jan 25, 2022 · Clinicians frequently prescribe antispasmodic agents to treat symptoms of abdominal pain, including spasms and cramps, in patients with DGBI.Missing: definition | Show results with:definition
  61. [61]
    Efficacy of soluble fibre, antispasmodic drugs, and gut–brain ...
    Dec 16, 2019 · We did a network meta-analysis of RCTs reporting the effect of soluble fibre, antispasmodic drugs, peppermint oil, and gut–brain neuromodulators ...
  62. [62]
    ACG Clinical Guideline: Management of Irritable Bowel Syndrome
    We recommend against the use of antispasmodics currently available in the United States to treat global IBS symptoms. Conditional recommendation; low quality of ...
  63. [63]
    Hyoscyamine Patient Tips: 7 things you should know - Drugs.com
    Sep 24, 2025 · Hyoscyamine is used to treat irritable bowel syndrome, gastrointestinal spasms, neurogenic bladder/bowel, infant colic, biliary/renal colic, ...
  64. [64]
    Irritable Bowel Syndrome - New England Journal of Medicine
    Dicyclomine (Bentyl). 10–20 mg 4 times daily. Mebeverine*. 135–200 mg 3 times daily. Otilonium bromide*. 20 mg 3 times daily. Cimetropium*. 50 mg 3 times daily.Missing: 1980s | Show results with:1980s
  65. [65]
    Oxybutynin - StatPearls - NCBI Bookshelf - NIH
    Aug 17, 2023 · Oxybutynin, an anticholinergic medication, is approved by the US Food and Drug Administration (FDA) and is indicated for patients with overactive bladder.
  66. [66]
    Oxybutynin extended release for the management of overactive ...
    This paper will review the major clinical studies involving oxybutynin ER as well as its role in different patient populations and potential concerns with its ...Missing: antispasmodics applications
  67. [67]
    Ipratropium - StatPearls - NCBI Bookshelf - NIH
    Ipratropium inhalation aerosol is a bronchodilator agent for chronic control of bronchospasms secondary to COPD, not a first-line medication for acute ...
  68. [68]
    Ipratropium: Uses, Interactions, Mechanism of Action - DrugBank
    Ipratropium is an anticholinergic drug used in the control of symptoms related to bronchospasm in chronic obstructive pulmonary disease (COPD).Identification · Pharmacology · Categories · References
  69. [69]
    Ipratropium-albuterol Inhalation - MedCentral
    Ipratropium bromide is used as a bronchodilator for the long-term symptomatic treatment of reversible bronchospasm associated with COPD.
  70. [70]
    Intrathecal baclofen in multiple sclerosis and spinal cord injury
    In multiple sclerosis and spinal cord injury patients, intrathecal baclofen therapy has a complication rate of 1% per month. Complications are mainly due to ...
  71. [71]
    Intrathecal Baclofen Therapy for Spinal Origin Spasticity
    Intrathecal baclofen is a safe, efficacious, titratable, reversible, and cost-effective treatment for severe spinal origin spasticity.
  72. [72]
    Cyclobenzaprine for acute back pain - PMC - NIH
    Bottom line. Cyclobenzaprine reduces pain and leads to global improvement compared with placebo for 1 in every 3 to 9 patients in the first week.
  73. [73]
    NSAID resistance in dysmenorrhea: epidemiology, causes, and ...
    In a double-blind crossover study, Kemp and colleagues demonstrated that hyoscine butylbromide was just as effective as aspirin in treating dysmenorrhea.
  74. [74]
    Antispasmodic/analgesic associations in primary dysmenorrhea ...
    Active treatments revealed significantly higher analgesic efficacy from the outset compared with baseline and placebo.
  75. [75]
    Tizanidine in cranial dystonia - PubMed
    Ten patients were enrolled in an open-label study with a single-blind placebo wash-in. Eight patients tolerated doses of between 28-36 mg per day. For the most ...
  76. [76]
    Dicyclomine Patient Tips: 7 things you should know - Drugs.com
    Jul 26, 2024 · 9% of people discontinue dicyclomine because of side effects. May cause drowsiness or blurred vision and affect your ability to drive or ...1. How It Works · 3. Downsides · 7. InteractionsMissing: incidence | Show results with:incidence
  77. [77]
    [PDF] FLEXERIL® (CYCLOBENZAPRINE HCl) Tablets - accessdata.fda.gov
    Evidence suggests that the net effect of cyclobenzaprine is a reduction of tonic somatic motor activity, influencing both gamma (γ) and alpha (α) motor systems.<|separator|>
  78. [78]
    Antispasmodic Side Effects: Common, Severe, Long Term - Drugs.com
    Sep 18, 2025 · Rare side effects. eye pain; skin rash or hives; sore throat and fever; unusual bleeding or bruising; yellow eyes or skin. See also: Xifaxan.
  79. [79]
    Side Effects of Muscle Relaxers - American Addiction Centers
    Mar 8, 2024 · Muscle relaxers have a potential for abuse and addiction. Prolonged use can lead to increased tolerance and physical dependence, especially with Soma.
  80. [80]
    Muscle Relaxants - LiverTox - NCBI Bookshelf - NIH
    Jan 30, 2017 · ... methocarbamol or orphenadrine are associated with significant liver injury and, if it occurs, hepatotoxicity from these agents must be ...
  81. [81]
    Medication-Related Problems in Older Adults - Merck Manuals
    Renal function is reduced in many older adults, resulting in decreased renal clearance and higher drug levels. Serious adverse effects include peptic ulceration ...
  82. [82]
    Risk of Injury in Older Adults Using Gastrointestinal Antispasmodic ...
    Jun 11, 2015 · Older adults using GI antispasmodic and anticholinergic drugs have greater risk of injury. These findings support recommendations to limit the prescribing of ...
  83. [83]
    [PDF] FLEXERIL (CYCLOBENZAPRINE HCL) TABLETS DESCRIPTION ...
    FLEXERIL may have life-threatening interactions with MAO inhibitors. (See. CONTRAINDICATIONS.) Postmarketing cases of serotonin syndrome have been reported.
  84. [84]
    [PDF] LYVISPAH (baclofen) Label - accessdata.fda.gov
    LYVISPAH is contraindicated in patients with hypersensitivity to baclofen. 5 WARNINGS AND PRECAUTIONS. 5.1 Adverse Reactions from Abrupt Withdrawal of LYVISPAH.
  85. [85]
    KEMSTRO™ (baclofen orally disintegrating tablets) - DailyMed
    Interactions. Drug interactions. The central nervous system depressant effects of baclofen may be additive to those of alcohol and other CNS depressants.
  86. [86]
    Antispasmodics: Uses and Side-Effects - Patient.info
    Dec 9, 2024 · Antispasmodics are used to treat symptoms such as abdominal pain and cramps (spasms). They are most often used for symptoms of irritable bowel syndrome.